查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1747658

全球第三代定序市場

Third Generation Sequencing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 271 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到2030年，全球第三代定序市場規模將達25億美元

全球第三代定序市場規模預計在2024年達到7.858億美元，預計到2030年將達到25億美元，2024年至2030年的複合年成長率為21.2%。本報告分析的細分市場之一－第三代定序產品，預計其複合年成長率為22.8%，到分析期結束時規模將達到18億美元。第三代定序服務細分市場在分析期間的複合年成長率預計為17.4%。

美國市場規模估計為 2.066 億美元，中國市場預計複合年成長率為 20.0%

美國第三代定序市場規模預計在2024年達到2.066億美元。預計到2030年，作為世界第二大經濟體的中國市場規模將達到3.802億美元，在2024-2030年的分析期內，複合年成長率為20.0%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為19.6%和18.1%。在歐洲，預計德國市場的複合年成長率約為14.4%。

全球「第三代定序」市場—主要趨勢與促進因素摘要

精準基因體學時代的第三代定序有何特色？

第三代定序 (TGS) 技術透過提供無需擴增的長讀長單分子序列，重新定義了基因組分析的模式。這種基於以往定序技術的演進對生物學研究、臨床診斷、農業和演化科學產生了深遠的影響。與嚴重依賴短讀長和易出錯的擴增過程的第二代技術不同，TGS 平台（例如 Pacific Biosciences 的 SMRT 和 Oxford Nanopore 的 MinION）能夠在包含重複序列、結構變異和表觀遺傳修飾的複雜基因組區域提供超長讀長和更高保真度的定序。這些能力對於從頭組裝完整基因組至關重要，尤其是在植物性因組、罕見疾病遺傳學和癌症異質性等先前頗具挑戰性的領域。研究人員也將 TGS 應用於轉錄組學，其中全長 mRNA定序可以精確檢測可變剪接和異構體表達。此外，TGS 還提供即時定序，可實現快速的周轉時間，這在感染疾病爆發期間以及在病原體監測和生物安全應用中至關重要。在定序過程中直接讀取 RNA 並檢測甲基化模式的能力使 TGS 成為基礎研究和臨床環境中的革命性技術。

即時可攜式定序是基因組診斷的未來嗎？

便攜性和即時分析是TGS平台的標誌，在臨床和現場環境中均提供無與倫比的靈活性。像Oxford Nanopore MinION這樣的設備足夠小巧，可以放進口袋，但功能又足夠強大，可以在野外進行複雜的基因組測序，無論是在偏遠的村莊、戰場還是太空站。這對公共衛生、流行病學和個人化醫療具有巨大的意義。在臨床診斷中，即時定序可以快速識別病原體，這對於敗血症管理、醫院內感染和癌症分析至關重要。在COVID-19大流行期間，TGS平台已在全球範圍內部署，用於即時病毒基因組追蹤，證明了其在監測突變和指南公共衛生應對方面的價值。在法醫學，TGS為DNA分析提供了一個新的精確度和整體性維度。可攜式平台還使農業科學家能夠在野外監測動植物性因組，有助於即時育種決策、疾病檢測和生物工程。這種移動性與即時數據輸出相結合，大大減少了對集中實驗室的需求，使得在資源有限的環境中也能進行高級測序，並為分散、快速和數據豐富的診斷打開了大門。

哪些技術進步推動了第三代定序的應用？

TGS 的進步是由分子生物學、生物資訊學和儀器工程的改進融合所驅動的。關鍵的發展包括提高通量、降低錯誤率和增強鹼基調用演算法，使 TGS 平台能夠匹配第二代準確度，同時保持長讀取的優勢。新酶化學、孔設計和訊號處理方法的引入增加了讀取長度和速度，同時降低了每個鹼基的成本。生物資訊工具也得到了發展，提供了可擴展的解決方案來處理 TGS 生成的龐大而複雜的資料集，而雲端基礎的平台促進了即時基因組數據的分析和共用。連接複用功能得到了擴展，使研究人員能夠同時對多個樣本進行測序而不會影響準確性。此外，樣品製備和自動化方面的創新正在減少勞動時間和污染風險。一些 TGS 工具的開放平台特性促進了廣泛的學術和工業合作，加速了特定應用的發現和客製化。這種技術勢頭使得TGS不僅成為舊方法的替代品，而且成為整個科學頻譜尖端研究和商業性突破的多功能推動者。

第三代測序市場的成長受到多種因素的推動。

第三代定序市場快速擴張是由技術、應用和行為動態共同驅動的。在醫療保健領域，對精準診斷和個人化治療計劃日益成長的需求需要能夠檢測複雜結構突變、罕見突變和表觀遺傳標記的定序工具。在腫瘤學領域，即時和全面定序正在加速向個人化癌症治療的轉變。在感染疾病監測中，TGS 能夠對病原體進行近乎即時的基因組分析。由於新出現的抗生素抗藥性菌株的增加，這種需求尤其迫切。在農業領域，對糧食安全和基因最佳化作物的追求刺激了 TGS 在植物和動物基因組分析中的應用。此外，直接面對消費者的基因檢測日益普及，引起了人們對能夠提供更深入見解的全面定序技術的興趣。為了反映向高解析度、高通量基因組科學的更廣泛轉變，學術機構和生物技術新興企業擴大將 TGS 平台納入其研究基礎設施。此外，利用行動裝置進行定序的去中心化正在改變使用者行為，並推動照護現場診斷和資料存取的民主化。這種技術主導和終端用戶特定的動態正在推動市場強勁的成長軌跡。

部分

組件（產品、服務）、技術（單分子即時定序、奈米孔定序、合成長讀定定序）、應用（基因測序、表觀遺傳學、轉錄組學、總體基因體學、其他應用）、最終用戶（生物製藥公司、醫院/診所、合約研究組織、其他最終用戶）

受訪公司範例（值得關注的34家公司）

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Complete Genomics, Inc.
  • Element Biosciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GenapSys, Inc.
  • Genia Technologies, Inc.
  • Illumina, Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Phase Genomics, Inc.
  • QIAGEN NV
  • Stratos Genomics, Inc.
  • Thermo Fisher Scientific Inc.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地、進出口（成品和原始OEM）來預測其競爭地位的變化。這種複雜且多面向的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

全球產業分析師密切關注來自全球頂尖首席經濟學家（14,949位）、智庫（62家）以及貿易和產業協會（171家）的專家的意見，以評估其對生態系統的影響並應對新的市場現實。我們追蹤了來自每個主要國家的專家和經濟學家對關稅及其對本國影響的看法。

全球產業分析師預計，這場動盪將在未來2-3個月內逐漸平息，新的世界秩序將更加清晰地建立。全球產業分析師正在即時追蹤這些事態發展。

2025年4月：談判階段

在4月的報告中，我們將探討關稅對全球整體市場的影響，並提供區域市場調整。我們的預測是基於歷史數據和不斷變化的市場影響因素。

2025年7月：最終關稅調整

在各國宣布最終重置後，客戶將在 7 月收到免費更新，最終更新將包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤了 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業以及各領域專家的最具影響力的首席經濟學家，他們共用了這場前所未有的全球經濟狀況模式轉移的影響。我們超過 16,491 份報告大多遵循基於里程碑的兩階段發布計劃。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 其他歐洲國家
  • 亞太地區
  • 其他地區

第4章 競賽

簡介目錄
Product Code: MCP35878

Global Third Generation Sequencing Market to Reach US$2.5 Billion by 2030

The global market for Third Generation Sequencing estimated at US$785.8 Million in the year 2024, is expected to reach US$2.5 Billion by 2030, growing at a CAGR of 21.2% over the analysis period 2024-2030. Third Generation Sequencing Products, one of the segments analyzed in the report, is expected to record a 22.8% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Third Generation Sequencing Services segment is estimated at 17.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$206.6 Million While China is Forecast to Grow at 20.0% CAGR

The Third Generation Sequencing market in the U.S. is estimated at US$206.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$380.2 Million by the year 2030 trailing a CAGR of 20.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 19.6% and 18.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.4% CAGR.

Global "Third Generation Sequencing" Market - Key Trends & Drivers Summarized

What Sets Third Generation Sequencing Apart in the Era of Genomic Precision?

Third Generation Sequencing (TGS) technologies have redefined the landscape of genomic analysis by offering long-read, single-molecule sequencing without the need for amplification. This evolution from earlier sequencing technologies has profound implications for biological research, clinical diagnostics, agriculture, and evolutionary science. Unlike second-generation methods, which rely heavily on short reads and error-prone amplification processes, TGS platforms such as Pacific Biosciences’ SMRT and Oxford Nanopore’s MinION deliver ultra-long reads with higher fidelity across complex genomic regions, including repetitive sequences, structural variants, and epigenetic modifications. These capabilities are critical for assembling complete genomes de novo, especially in previously intractable areas like plant genomes, rare disease genetics, and cancer heterogeneity. Researchers are also applying TGS to transcriptomics for full-length mRNA sequencing, allowing for accurate detection of alternative splicing and isoform expression. Additionally, TGS offers real-time sequencing, enabling rapid turnaround times critical during infectious disease outbreaks and for applications in pathogen surveillance and biosecurity. The ability to directly read RNA and detect methylation patterns during sequencing positions TGS as a transformative technology in both foundational research and clinical practice.

Is Real-Time and Portable Sequencing the Future of Genomic Diagnostics?

Portability and real-time analysis are hallmarks of TGS platforms, offering unmatched flexibility in both clinical and field environments. Devices like the Oxford Nanopore MinION are compact enough to fit in a pocket yet powerful enough to perform complex genomic sequencing on-site-be it a remote village, a battlefield, or a space station. This has enormous implications for public health, epidemiology, and personalized medicine. In clinical diagnostics, real-time sequencing enables faster pathogen identification, crucial in sepsis management, hospital-acquired infections, and cancer profiling. During the COVID-19 pandemic, TGS platforms were deployed globally for real-time viral genome tracking, showcasing their value in monitoring mutations and guiding public health responses. In forensic science, TGS offers new dimensions of accuracy and comprehensiveness for DNA profiling. Portable platforms are also enabling agricultural scientists to monitor plant and animal genomes in the field, aiding in real-time breeding decisions, disease detection, and bioengineering. This mobility-combined with real-time data output-greatly reduces the need for centralized laboratories, making advanced sequencing accessible even in resource-limited settings and opening the door to decentralized, rapid, and data-rich diagnostics.

What Are the Technological Advancements Driving Adoption of Third Generation Sequencing?

The progress in TGS is driven by a convergence of improvements in molecular biology, bioinformatics, and instrument engineering. Key developments include increased throughput, reduced error rates, and enhanced basecalling algorithms that now allow TGS platforms to rival second-generation accuracy while preserving the advantages of long reads. The introduction of new enzyme chemistries, pore designs, and signal processing methods has improved read lengths and speed, while simultaneously lowering costs per base. Bioinformatics tools have also advanced, offering scalable solutions to handle the vast and complex datasets generated by TGS, with cloud-based platforms facilitating real-time genomic data analysis and sharing. Multiplexing capabilities are expanding, allowing researchers to sequence multiple samples concurrently without compromising accuracy. Additionally, innovations in sample preparation and automation are reducing hands-on time and contamination risks. The open-platform nature of some TGS tools has encouraged broad academic and industrial collaboration, accelerating discovery and customization for specific applications. This technological momentum is positioning TGS not just as a replacement for older methods, but as a versatile enabler of cutting-edge research and commercial breakthroughs across a spectrum of scientific disciplines.

The Growth in the Third Generation Sequencing Market Is Driven by Several Factors…

The rapid expansion of the third generation sequencing market is being fueled by a combination of technological, application-specific, and behavioral dynamics. In the healthcare sector, the increasing demand for precision diagnostics and personalized treatment plans is necessitating sequencing tools capable of detecting complex structural variations, rare mutations, and epigenetic markers-capabilities where TGS outperforms conventional methods. In oncology, real-time and comprehensive sequencing is accelerating the shift toward individualized cancer therapies. In infectious disease surveillance, TGS enables near-instantaneous genomic analysis of pathogens, a need that has become especially urgent with the rise of emerging and antibiotic-resistant strains. In agriculture, the push for food security and genetically optimized crops is spurring adoption of TGS in plant and animal genomics. Furthermore, the growing popularity of direct-to-consumer genetic testing is driving interest in more comprehensive sequencing technologies that offer deeper insights. Academic institutions and biotech startups are increasingly incorporating TGS platforms into their research infrastructures, reflecting a broader transition to high-resolution, high-throughput genomic science. The decentralization of sequencing-empowered by portable devices-is also transforming user behavior, encouraging point-of-care diagnostics and democratized data access. These technology-driven and end-use-specific dynamics are collectively propelling the market’s robust growth trajectory.

SCOPE OF STUDY:

The report analyzes the Third Generation Sequencing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Component (Products, Services); Technology (Single-molecule Real-time Sequencing, Nanopore Sequencing, Synthetic Long-read Sequencing); Application (Genome Sequencing, Epigenetics, Transcriptomics, Metagenomics, Other Applications); End-User (Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • 10x Genomics
  • Agilent Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Complete Genomics, Inc.
  • Element Biosciences, Inc.
  • Eurofins Scientific
  • F. Hoffmann-La Roche AG
  • GATC Biotech AG
  • GenapSys, Inc.
  • Genia Technologies, Inc.
  • Illumina, Inc.
  • Loop Genomics
  • Nabsys, Inc.
  • Oxford Nanopore Technologies
  • Pacific Biosciences of California, Inc.
  • PerkinElmer, Inc.
  • Phase Genomics, Inc.
  • QIAGEN N.V.
  • Stratos Genomics, Inc.
  • Thermo Fisher Scientific Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Third Generation Sequencing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Real-Time, Long-Read Sequencing Propels Market Growth
    • Accelerated Adoption in Clinical Diagnostics Expands Addressable Market
    • Rising Incidence of Genetic Disorders and Cancer Drives Sequencing Uptake
    • Demand for Deeper Genome Insights Strengthens Business Case for Third Gen Platforms
    • Government Genomic Initiatives and Grants Spur R&D and Market Entry
    • Advances in Bioinformatics Tools Enhance Accuracy and Usability of Sequencing Data
    • Growing Use in Agriculture and Animal Genomics Broadens Market Scope
    • Declining Cost per Genome Sequenced Drives Mass Adoption
    • Personalized Medicine Boom Throws Spotlight on Rapid Sequencing Technologies
    • Emerging Use Cases in Pathogen Surveillance Sustain Market Momentum
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Third Generation Sequencing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Third Generation Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Genome Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Genome Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Epigenetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Epigenetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Transcriptomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Transcriptomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Metagenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Metagenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Biopharmaceutical Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Biopharmaceutical Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Single-molecule Real-time Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Single-molecule Real-time Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Nanopore Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Nanopore Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Synthetic Long-read Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Synthetic Long-read Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • JAPAN
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • CHINA
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • EUROPE
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Third Generation Sequencing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Third Generation Sequencing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • FRANCE
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • GERMANY
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Third Generation Sequencing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 182: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Component - Products and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of World Historic Review for Third Generation Sequencing by Component - Products and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of World 15-Year Perspective for Third Generation Sequencing by Component - Percentage Breakdown of Value Sales for Products and Services for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of World Historic Review for Third Generation Sequencing by Application - Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of World 15-Year Perspective for Third Generation Sequencing by Application - Percentage Breakdown of Value Sales for Other Applications, Genome Sequencing, Epigenetics, Transcriptomics and Metagenomics for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of World Historic Review for Third Generation Sequencing by End-user - Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of World 15-Year Perspective for Third Generation Sequencing by End-user - Percentage Breakdown of Value Sales for Biopharmaceutical Companies, Hospitals & Clinics, Contract Research Organizations and Other End-Users for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of World Recent Past, Current & Future Analysis for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of World Historic Review for Third Generation Sequencing by Technology - Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of World 15-Year Perspective for Third Generation Sequencing by Technology - Percentage Breakdown of Value Sales for Single-molecule Real-time Sequencing, Nanopore Sequencing and Synthetic Long-read Sequencing for the Years 2015, 2025 & 2030

IV. COMPETITION